BGAI
RPRX icon

Bruce G. Allen Investments’s Royalty Pharma RPRX Stock Holding History

Bruce G. Allen Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.98K Hold
178
– – 0.01% 486
2026
Q1 		$8.54K Hold
178
– – 0.01% 508
2025
Q4 		$6.88K Hold
178
– – ﹤0.01% 520
2025
Q3 		$6.28K Hold
178
– – ﹤0.01% 523
2025
Q2 		$6.41K Buy
178
+7
+4% +$232 ﹤0.01% 530
2025
Q1 		$5.32K Sell
171
-19
-10% -$602 ﹤0.01% 560
2024
Q4 		$4.85K Buy
190
+13
+7% +$345 ﹤0.01% 579
2024
Q3 		$5.01K Sell
177
-44
-20% -$1.22K ﹤0.01% 580
2024
Q2 		$5.83K Sell
221
-320
-59% -$8.87K ﹤0.01% 545
2024
Q1 		$16.4K Buy
541
+185
+52% +$5.45K 0.01% 402
2023
Q4 		$10K Buy
+356
New +$9.78K 0.01% 476

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bruce G. Allen Investments's RPRX Position: Q2 2026 in Review

Bruce G. Allen Investments held its Royalty Pharma (RPRX) position steady in Q2 2026 at 178 shares worth $9.98K. The position accounts for 0.01% of the portfolio, ranked #486.

Bruce G. Allen Investments first reported a position in RPRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $16.4K in Q1 2024. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Bruce G. Allen Investments held 178 shares of Royalty Pharma worth $9.98K as of Q2 2026.
  • Bruce G. Allen Investments left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.01% of Bruce G. Allen Investments's portfolio in Q2 2026, its #486 holding.
  • Bruce G. Allen Investments first reported a position in Royalty Pharma in Q4 2023 and has held it in 11 quarters since.
  • Bruce G. Allen Investments's Royalty Pharma position peaked at $16.4K in Q1 2024.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Bruce G. Allen Investments's 13F filing for Q2 2026, filed 31 Jul 2026.